Skip to main content
. 2013 Oct 22;113(1):157–167. doi: 10.1093/bja/aet338

Fig 2.

Fig 2

TREK-1 mediates sevoflurane preconditioning-induced neuroprotection in vitro. (a) Western blot analysis showing the efficiency of TREK-1 siRNA knockdown of the expression of TREK-1 in differentiated SH-SY5Y cells. Normal, untreated control cells; siRNA, cells treated with TREK-1 siRNA; siRNA-c, cells treated with AllStars Negative Control siRNA. Note that protein expression of TREK-1 was inhibited by TREK-1 siRNA compared with either the normal or siRNA-c group. Data presented as mean (sem). *P<0.05 compared with the normal control group. (b) Histograms showing cell viabilities in the normal (control), OGD, sevoflurane preconditioning plus OGD (Pre+OGD), TREK-1 siRNA plus sevoflurane preconditioning plus OGD (siRNA+Pre+OGD), or control siRNA plus sevoflurane preconditioning plus OGD (siRNA−c+Pre+OGD) groups. *P<0.05 vs OGD group. #P<0.05 vs Pre+OGD group. (c) Western blot analysis for caspase-3 expression. Data presented as mean (sem). *P<0.05 vs the OGD group. #P<0.05 compared with the Pre+OGD group. (d) Representative immunofluorescence images showing activation of caspase-3 in SH-SY5Y cells at 24 h after OGD. Bar=20 μm.